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The mode of action of the glycocins is still unknown. The glycocin family is unusual due to the 
rarity of glycosylated peptides in bacteria and of cysteine S-glycosylations in general. S-
glycosylation of cysteine has previously been shown to result in a metabolically more stable 
conjugation than the more common O-glycosylation of serine. This stabilization is supported by 
the high stability of sublancin and may explain the need for glycosylation in sublancin for 
antimicrobial activity. Previous studies have shown that the deletion of and mutations in the 
glucose phosphotransferase system confer resistance to sublancin. In this work we add to this 
knowledge by generating new sublancin-resistant mutants in B. subtilis 168 ΔSPβ. The mutations 
found support previous findings but also demonstrate the need to look for larger genome changes 
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CHAPTER 1: SUBLANCIN AND THE GENERATION OF SUBLANCIN-RESISTANT 
MUTANT B. SUBTILIS 168 ΔSPΒ 
 
1.1 INTRODUCTION 
The discovery and development of antibiotics is one of the greatest achievements of 
modern medicine. However, the overuse and abuse of antibiotics has led to a spreading of 
antibiotic resistance that may become a significant threat to world health. The World Health 
Organization (WHO) estimates that 700,000 deaths per year worldwide are due to antimicrobial 
resistance. If nothing is done to counteract this resistance, the number of deaths is estimated to 
increase to 10 million by 2050.1 The van der Donk lab seeks to help fill the void for novel 
antibiotics by studying the biosynthesis of ribosomally-synthesized and post-translationally 
modified peptide (RiPP) natural products.2  
The increase in antibiotic resistance less than a century after the first development of 
antibiotics for human use is an evolutionary inevitability that has been complicated by the 
overuse, abuse, and poor regulation of antibiotics. New antibiotics will always be needed; 
however, the number of new antibiotics entering the market has strongly declined in recent 
decades. This is largely due to the high cost of developing a lead compound, the low success rate 
of regulatory approval, and the relatively low return on investment. Development of new 
antibiotics in the pharmaceutical industry is also hampered by the rediscovery of already known 
antibiotics.3  
For the first few decades of antibiotic discovery and development, activity was typically 
detected as zones of growth inhibition on lawns of sensitive bacteria in response to either the 
antibiotic producer or a lead compound. This ‘low hanging fruit’ approach was so successful that 
2 
 
by the 1970s the rate of antibiotic discovery had slowed dramatically.1,4,5 With the advent of 
powerful DNA sequencing technologies, many laboratories have suggested that the future of 
antibiotic discovery lies in mining the genomes of bacteria for silent biosynthetic gene clusters. 
By looking for unique gene clusters we may be able to predict the structure and function of novel 
antibiotics with undiscovered antimicrobial activity. 
One antibiotic discovered by the activity-based fractionation approach is the RiPP 
produced by B. subtilis 168, sublancin. First described in 1998 by Paik et al. it was not until 2011 
that study of the biosynthetic enzymes revealed sublancin was not a lantibiotic but an S-linked 
glycopeptide.6,7 The purpose of this novel glycosylation is still under investigation but it has 
been found to be essential for bioactivity.  
 
1.2 INTRODUCTION TO GLYCOCINS / SUBLANCIN 
Sublancin is a member of a fast-growing collection of RiPP natural compounds. RiPP 
modifications typically convert a linear peptide into a more rigid, often cyclic, structure. Many of 
the studied RiPPs are comprised of an N-terminal leader peptide followed by a C-terminal core 
peptide. The N-terminal peptide is believed to direct enzymatic modification of the core peptide. 
Subsequent cleavage of the N-terminal peptide leads to a fully modified biologically active core 
peptide.2,8  
First identified in B. subtilis 168, sublancin has shown extreme thermal stability and good 
antimicrobial activity against medically relevant Gram-positive bacteria such as methicillin 
resistant Staphylococcus aureus (MRSA).6 The mechanisms used by glycocins to kill bacteria are 
currently unknown. Glycocins are characterized by the glycosylation of either a cysteine or 
serine residue and two nested disulfide bonds. While sublancin was initially thought to be a 
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lantibiotic, the mass spectrometry (MS) and nuclear magnetic resonance (NMR) data have 
shown sublancin to be a novel S-linked glycopeptide.9  
 
1.3 GENE ORGANIZATION 
Glycocin biosynthetic genes are clustered and do not currently have a universal gene 
designation. Sublancin biosynthetic genes have been designated as sun and serve as an excellent 
model for almost all known glycocins. The biosynthetic gene cluster encodes a precursor peptide 
(SunA), a glycosylation enzyme (SunS), two thiol-disulfide oxidoreductases (BdbA and BdbB), 
an immunity protein (SunI), and a bifunctional transporter/protease (SunT). All of these genes 
are located on a SPβ prophage which has integrated into the chromosome of B. subtilis 168. 
Biosynthesis of sublancin has been shown to first require glycosylation by SunS, followed by 
peptide folding by BdbA and BdbB. Finally, the leader peptide is removed and transported out of 
the cell by SunT.7  
 
1.4 THE ROLE OF THE PHOSPHOTRANSFERASE SYSTEM IN SUBLANCIN 
SENSITIVITY 
The importance of the phosphotransferase system (PTS) was first discovered 
independently by the van Dijl and van der Donk groups. The van Dijl Lab found that the deletion 
of the PTS operon (ptsGHI) resulted in resistance to sublancin in a sensitive strain of B. subtilis 
168. Of note for later discussion, the van Dijl group also found that the deletion of glcT,10 which 
acts as a regulator of the PTS operon, did not confer sublancin resistance.  At the same time, 




The glucose phosphotransferase system is comprised of three genes. ptsG encodes the 
major glucose transporter and is comprised of three domains (EIIA, EIIB, & EIIC).11 PtsH and 
PtsI, better known as Histidine Protein (HPr) and Enzyme E I (EI) respectively, are general 
components of the phosphotransferase system, capable of aiding in the transport of any sugar 
molecule that uses the PTS, not only glucose. In B. subtilis 168, the phosphoryl group of 
phosphoenolpyruvate is transferred successively to conserved histidine residues in EI, HPr, and 
then EIIA. EIIA is specific for glucose and transfers the phosphoryl group to a cysteine residue 
on EIIB. Finally, EIIB phosphorylates glucose as it crosses the plasma membrane through the 
transmembrane domain EIIC forming glucose-6-phosphate.12 The phosphorylated sugar can then 
enter glycolysis. 
To investigate resistance to sublancin, Dr. Garcia de Gonzalo performed comparative 
genomic analysis of sublancin-resistant B. halodurans C-125. Mutants were generated by 
treating B. halodurans C-125 with sublethal concentrations of sublancin in Luria broth (LB). Of 
the four sublancin-resistant mutants that she analyzed for SNPs and small indels, sublancin-
resistant B. halodurans C-125 001 contained three mutations in the region between the 
transcriptional antiterminator (glcT) and the pts operon (ptsGHI), while sublancin-resistant B. 
halodurans C-125 003 contained one non-sense mutation in the PTS glucose-specific subunit 
IIA. Sublancin-resistant B. halodurans C-125 002 had one missense mutation in the gene for 
mannitol-1-phosphate 5-dehydrogenase, which is indirectly involved in the glucose pts. 
Sublancin-resistant B. halodurans C-125 004 had no significant SNPs or indels, yet maintained 
resistance to sublancin. 
Based on these results, new sublancin-resistant mutants were generated in this study 
using the sublancin sensitive strain prepared by the van Dijl group, B. subtilis 168 ΔSPβ. This 
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strain has been shown to be more sensitive to sublancin than B. halodurans C-125 and has more 
tools available for genetic manipulation and analysis. The mutants were also generated in media 
where the carbon source was restricted to potentially force mutations outside of the glucose pts.  
 
1.5 GENERATION OF SUBLANCIN-RESISTANT MUTANTS IN MINIMAL MEDIA 
Dr. Garcia de Gonzalo’s bioassays of reconstituted sublancin and its analogs carrying 
different sugars against B. halodurans C-125 and sublancin-resistant B. halodurans C-125 
demonstrated that the mutation(s) that allowed for sublancin-resistance were unable to grow in 
M9 minimal media where glucose is the sole carbon source. These mutants were generated using 
sublethal concentrations of sublancin in LB media where the bacteria had ample access to 
alternative carbon sources. In order to investigate potential resistance mechanisms further, I 
generated sublancin-resistant mutants in M9 minimal media where the sole carbon source was 
either mannose or glucose. By generating sublancin-resistant mutants under these conditions we 
hoped it would force the bacteria to make mutations outside of the glucose-phosphotransferase 
system, since in one case (mannose) the pts is not essential, whereas in the other (glucose) 
mutations in the pts would not allow the bacteria to grow.  
For these experiments, B. subtilis 168 ΔSPβ was used as the wild-type. B. subtilis 168 is a 
long-studied bacterium which is auxotrophic for tryptophan, requiring supplemental amounts of 
trp for proper growth.  In B. subtilis 168, the SP-beta prophage contains all the genes required for 
the production of sublancin. Deletion of the SP-beta prophage has been shown to result in 
increased sensitivity to sublancin compared to B. halodurans C-125.13  
The complete genome sequences of eight sublancin-resistant mutants grown in M9 
(glucose) and seven mutants grown in M9 (mannose) of B. subtilis 168 ΔSPβ were analyzed for 
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SNPs and indels. In all but one genome, mutations were found in either the glc-PTS or genes 
involved in the regulation of the glc-PTS, glcT and glcR. Mutations in the glcT gene were found 
in one of the mutants (Mut 6) grown in M9 glucose and four of the mutants (Mut 1, 3, 4, & 7) 
grown in M9 mannose. These findings in part contradict what the van Dijl group found when 
they deleted the glcT gene and found no resistance was conferred. All of the mutations in the 
ptsG gene were found in subunit EIIC. 
 
Table 1.1: Sublancin-resistant mutants of B. subtilis 168 ΔSPβ grown in M9 minimal media with 
glucose as the sole carbon source. 
Mutant Position 
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Table 1.2: Sublancin-resistant mutants of B. subtilis 168 ΔSPβ grown in M9 minimal media with 
mannose as the sole carbon source. 
Mutation Position
(s) 
Gene SNP INDEL Allele 
freq. 
Misc. 
Mut1ManBacillus 161239 rrna32 (exon, 
noncoding 
modifier) 
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gained, high 
impact) 
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C --> T  0.714 Peptidoglycan O-
acetlytransferase. 
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Table 1.2 (cont.) 
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Mut7ManBacillus 
 2088982 yocD (silent, 
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G --> C  0.143 Putative 
carboxypeptidase. 
Only observed in 
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 2771956 oatA (silent, 
low impact) 
C --> T  0.714 Peptidoglycan O-
acetyltransferase. 
Only observed in 
Mut 2, 3, 4, 6, & 7 
 
It is important to note that two of the four sublancin-resistant mutants of B. halodurans 
C-125 prepared by Dr. Garcia de Gonzalo also conferred resistance despite the lack of significant 
SNPs and indels found in the analyzed genomes.  
Although other methods of glucose transport exist, the PTS is the major glucose uptake 
system in enteric bacteria.14 In the future it may be necessary to search for larger architectural 
changes such as large intergenic mutations. It is possible that to avoid deleterious mutations the 
regulation of the PTS is being altered by large transposable elements.  
Thus, whereas we had hoped that using minimal media with either mannose or glucose as 
the sole carbon source would lead to mutations in additional potential targets of sublancin, our 
results show that the PTS was still the locus of mutant generation. These results suggest that the 




CHAPTER 2: EXPERIMENTAL PROCEDURES FOR THE GENERATION AND 
ANALYSIS OF SUBLANCIN-RESISTANT MUTANTS OF B. SUBTILIS 168 ΔSPΒ 
 
2.1 PRODUCTION OF SUBLANCIN 
Isolation of soluble sublancin was described previously by Dr. Trent Oman.7 Overnight 
cultures of B. subtilis 168 were grown under aerobic conditions at 37 ⁰C for 12-15 h. The 
overnight cultures were used to inoculate 500 mL of Medium A (at 1%) in 2 L flasks. Medium A 
is comprised of 900 mL of a Medium A nutrient broth and 100 mL of 10X Medium A salts. The 
Medium A nutrient broth consists of 20 g sucrose, 11. 7 g citric acid, 4 g Na2SO4, 4.2 g 
(NH4)2HPO4, and 5 g yeast extract all dissolved in 900 mL of deionized water. The pH was 
adjusted to 6.8-6.9 using NaOH and the medium was autoclaved. The 10X Medium A salts is 
comprised of 7.62 g KCl, 4.18 g MgCl2-6 H2O, 0.543 g MnCl2-4 H2O, 0.49 g FeCl3-6 H2O, and 
0.208 g ZnCl2 dissolved in 1 L of deionized water followed by sterilization using a 0.22 mm 
filtration device. The cultures were grown in medium A under aerobic conditions at 37 ⁰C for 28-
48 h with agitation at 210 rpm. A pinkish-brown color change and drop in pH (~5.0-6.0) is 
typically observed after 15 h and is consistent with sublancin production. The cultures are then 
grown an additional 24-48 h after the color change is observed. 
The cultures were acidified to pH 2.5 with concentrated phosphoric acid (85% in water) 
and centrifuged at 6000x rcf for 10 min at 4 ⁰C to remove cells and insoluble material. Soluble 
sublancin was isolated from the supernatant by ammonium sulfate precipitation. In a 2 L flask, 
490 g (NH4)2SO4 per 1 L was combined with the sublancin-containing supernatant. It is 
important to dissolve the (NH4)2SO4 in several small batches over 20-30 min at 4 ⁰C. The 
precipitation mixture was stirred for 24 h at 4 ⁰C. Crude sublancin was precipitated by 
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centrifugation at 5000x rcf for 30 min at 4 ⁰C. After carefully disposing of the supernatant, a thin 
brownish film of sublancin-containing precipitant was re-suspended in 1:1 ACN:water and 
analyzed by MALDI-TOF MS to confirm it contained sublancin. A 1 L aliquot of the 
precipitant was combined with 1 L of saturated solution of -cyano-4-hydroxy- cinnamic acid 
matrix in 1:1 ACN: water with 0.1% TFA. The total volume was spotted onto a MALDI plate 
and dried under ambient conditions prior to analysis. The crude sublancin suspension can be 
lyophilized, and stored under N2 at -80 ⁰C until purification by preparative HPLC. 
Preparative HPLC was performed on a Shimadzu HPLC with a Phenomenex Jupiter C12 
column equilibrated in 2% solvent B (solvent A = 0.1% TFA in water, solvent B = 0.0866% 
TFA in 80% ACN/20% water). Crude sublancin was re-suspended in 10 mL of 2% solvent B. 
The solution was spun down at 4500x rcf for 10 min at 4 ⁰C to pellet insoluble peptides. The 
crude sublancin was filtered using a 0.45 PDVF filter before loading the sample on to the HPLC 
column. Sublancin was eluted by maintaining the mobile phase at 2% B for 1 min, followed by 
an increase to 100% B over 35 min with a flow rate of 8.0 mL/min. Sublancin eluted at 23.0- 
24.2 min. All fractions were analyzed by MALDI-TOF MS as described above. Purified 
sublancin was lyophilized and stored under N2 at -80 ⁰C. Yields were typically 6-8 mg sublancin 
per liter of Medium A culture. 
 
2.2 GENERATION OF SUBLANCIN-RESISTANT B. SUBTILIS 168 ΔSP 
Sublancin-resistant B. subtilis 168 ΔSPβ was generated by treating cells with sublethal 
amounts of sublancin in liquid M9 minimal medium with 50 µg/mL tryptophan and either 4 g/L 
mannose or 4 g/L glucose as the sole carbon source. Enriching for mutants was achieved by 
plating on agar plates with the same nutrient composition but 4x the MIC of sublancin. Single 
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colonies were selected and grown in identical liquid minimal medium again with 4x the MIC of 
sublancin. The minimal inhibitory concentration (MIC) against the wt strain was determined to 
be 1 µM (man) and 25 µM (glc) under these growth conditions. The experiment was performed 
as described below. For cells grown in M9 minimal media with 50 µg/mL tryptophan (required 
for this B. subtilis strain) where mannose was the sole carbon source, dilutions of 0.03125-2.0 
µM sublancin were used.15 For cells where glucose was the sole carbon source dilutions of 1.56-
100 µM sublancin were required. Stock sublancin solutions were filtered using costar spin-x 
filters (0.22 µm) for 3 min at 1.7 x 103 rpm. Using a sterile 96 well plate the total volume of 
culture in each well was 100 µL. 10 µL of 10x stock sublancin at defined concentrations and 90 
µL of a 1-in-10 dilution (approximately 1 x 108 colony-forming units (CFU) mL-1) of a culture of 
B. subtilis 168 ∆SPβ with M9 minimal medium (glc or man). The following negative controls 
were prepared 1.) 90 µL of a 1-in-10 dilution of a culture of B. subtilis 168 ∆SPβ and 10 µL of 
M9 minimal medium (glc or man) and 2.) 100 µL of M9 minimal medium (glc or man). The 96-
well plate was incubated at 37 ⁰C, with shaking at 250 rpm for 28 h. The optical density at 600 
nm (O.D.600 nm) was recorded at half hour intervals from 0 to 28 h using a BioTek Synergy 4H 
plate reader. The readings of triplicate experiments were averaged.  
10 L of sublancin-resistant B. subtilis 168 ∆SPβ that was generated at the MIC (1 µM-
man, 25 µM-glc) was used to inoculate M9 minimal media (5 mL with 50 µg/mL tryptophan, 4 
g/L mannose or glucose) at 4x MIC to retain any mutations. After incubating at 37 ⁰C, 250 rpm 
for 4-5 h the cultures were streaked for colony isolation on M9 minimal media agar plates (50 
g/mL tryptophan, 4 g/L mannose or glucose, and 4x MIC sublancin) and placed in the incubator 
overnight at 37 ⁰C. Several colonies were picked and grown overnight in liquid M9 minimal 
media (50 g/mL tryptophan, 4 g/L mannose or glucose, and 4x MIC sublancin).  These samples 
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were now considered to only contain sublancin-resistant B. subtilis 168 ∆SPβ. Glycerol stocks 
were prepared and stored at − 80 ⁰C. 
 
2.3 READ PREPARATION OF MUTANT SAMPLES 
The following procedure was developed by Gloria Rendon at the Roy J. Carver 
Biotechnology Center. The shotgun genomic libraries were prepared with the Hyper Library 
construction kit from Kapa Biosystems. The libraries were quantitated by qPCR and sequenced 
on one lane for 151 cycles from each end of the fragments on a HiSeq 4000 using a HiSeq 4000 
sequencing kit version 1. Fastq files were generated and demultiplexed with the bcl2fastq 
v2.17.1.14 Conversion Software (Illumina). Each paired read was 150 nt in length. The size of 
the genome is 4.14 Mb and the read coverage is ~3000x. 
The file names of the samples were assigned by me and they include strings that indicate 
the kind of treatment that they received prior to DNA extraction and sequencing.  Samples that 
received the glucose treatment had filenames with this pattern Mut#GlcBacillusMRG where [#] 
is a digit. Samples that received the mannose treatment had filenames with this pattern 
Mut#ManBacillusMRG. 
Paired reads of each sample were aligned against the reference genome of Bacillus 
subtillis 16816 with bwa17 version 1.7.12, with default parameters. Then deduplication was 
performed with MarkDuplicates, part of Picard-tools18 version 2.4.1. Finally sorting by 
coordinates was done with novosort, part of novocraf19 version 3.02. The resulting file is 
sometimes called “analysis-ready reads” and its format is BAM.20 
The same variant discovery pipeline for DNA samples was run on the raw reads of the 
wild type strain, and 30 raw variants compared to the reference genome were discovered in this 
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sample.  These raw variants were then annotated with functional information in the same way 
used for the 15 mutant samples; that is, functional annotations with SnpEff and with GATK’s 
VariantAnnotator. Figure 2.1 shows the result of one of the reports generated by SnpEff on this 
sample. 
 
Figure 2.1. SnpEff classification of variants found in WT strain. 
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